Pegasus Technologies

www.pegatech.com
Israel
SEARCH FILTERS
Time filter
Source Type

Gunby J.,Pegasus Technologies | Bissonnette F.,University of Montréal | Librach C.,University of Toronto | Cowan L.,Victoria Fertility Center
Fertility and Sterility | Year: 2011

Objective: To present a report on assisted reproductive technologies (ART) cycles performed in 2007 in Canada and show trends in outcomes over time. This is the seventh annual report from the Canadian ART Register (CARTR). Design: Prospective cohort study. Setting: Twenty-six of 26 ART centers in Canada. Patient(s): Couples undergoing ART treatment in Canada during 2007. Intervention(s): ART treatments, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and frozen embryo transfer (FET). Main Outcome Measure(s): Clinical pregnancy, live-birth, and multiple-birth rates. Result(s): A total of 13,482 ART cycles was reported to CARTR. In 8,972 IVF/ICSI cycles using the woman's own oocytes, per cycle started, the clinical pregnancy rate was 35.6% (41.0% per ET), and the live-birth rate was 28.6%; the multiple-birth rate per delivery was 30.2%, with a high-order multiple-birth rate of 1.1%. In 68% of cycles ICSI was performed. One or two embryos were transferred in 69% of cycles. In 404 IVF/ICSI cycles using donor oocytes, the clinical pregnancy rate was 44.6%, and the live-birth rate was 36.1%; the multiple-birth rate was 26.5%, with no triplet birth. In 3,224 FET cycles using the woman's own oocytes, the clinical pregnancy rate was 23.7%, and the live-birth rate was 17.8%; the multiple-birth rate was 24.1%, with a triplet birth rate of 0.2%. Birth outcomes were unknown for 2.0% of ongoing pregnancies. Conclusion(s): For 2007, CARTR achieved 100% voluntary participation from Canadian ART centers for the fifth consecutive year. Clinical pregnancy and live-birth rates continued to increase in 2007 compared with previous years, with a decrease in high-order multiple births. © 2011 American Society for Reproductive Medicine, Published by Elsevier Inc.


Gunby J.,Pegasus Technologies | Bissonnette F.,University of Montréal | Librach C.,Womens College Hospital | Cowan L.,Victoria Fertility Center
Fertility and Sterility | Year: 2010

Objective: To present a report on assisted reproductive technologies (ART) cycles performed in 2006 in Canada and show trends in outcomes over time. This is the sixth annual report from the Canadian ART Register (CARTR). Design: Prospective cohort study. Setting: Twenty-five of 25 ART centers in Canada. Patient(s): Couples undergoing ART treatment in Canada during 2006. Intervention(s): ART treatments, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and frozen embryo transfer (FET). Main Outcome Measure(s): Clinical pregnancy, live birth, and multiple birth rates. Result(s): A total of 12,052 ART cycles was reported to CARTR. In 8278 IVF/ICSI cycles using the woman's own oocytes, the clinical pregnancy rate per cycle started was 33.7% (38.6% per ET), and the live birth rate was 27.1%; the multiple birth rate per delivery was 30.3%, with a high-order multiple birth rate of 1.5%. In 64% of cycles, ICSI was performed. One or two embryos were transferred in 67% of cycles. In 350 IVF/ICSI cycles using donor oocytes, the clinical pregnancy rate was 42.3%, and the live birth rate was 33.6%; the multiple birth rate was 37.3%, with no triplet birth. In 2838 FET cycles using the woman's own oocytes, the clinical pregnancy rate was 24.3%, and the live birth rate was 18.6%; the multiple birth rate was 22.5%, with a triplet birth rate of 0.6%. Birth outcomes were unknown for 3.6% of ongoing pregnancies. Conclusion(s): For 2006, CARTR achieved 100% voluntary participation from Canadian ART centers for the fourth consecutive year. Clinical pregnancy and live birth rates continued to increase in 2006 compared with previous years, but multiple birth rates decreased only slightly. © 2010 by American Society for Reproductive Medicine.


Rubinsky L.,Pegasus Technologies | Patrick B.,Pegasus Technologies | Patrick B.,Exponent, Inc. | Mikus P.,Pegasus Technologies | And 2 more authors.
Biomedical Microdevices | Year: 2016

We describe a new wound dressing technology that can actively generate an inorganic germicide agent, in situ, within the wound pad. The technology provides real time control over the quantitative, spatial and temporal delivery of the germicide. The identity of the germicide is hypochlorous acid (HClO). The HClO is produced in a flexible wound pad, made of a composite of thin (micrometer scale) layers of various materials, with different electrochemical properties that enhance HClO production. Active control over the production of HClO is achieved by control of the pH and of the electric potential across the layers. The effectiveness of the Active HClO Pad (AHClOP) concept is demonstrated in a study on sterilization of E. coli in a deep wound contamination simulating gel. The performance of the AHClOP is compared with that of four commercial wound dressings. Results show that the AHClOP can sterilize throughout the gel, while the commercial dressings cannot. © 2016, Springer Science+Business Media New York.


Patent
Pegasus Technologies | Date: 2011-03-09

The present invention concerns a handheld device (300) for use with a board or screen supplemented with a processing system for digitizing operative strokes of the handheld device on the board or screen, the handheld device comprising:(a) a housing (302) having a substantially cylindrical bore (304) therein terminating at a distal end (306) of said housing with a central orifice (308) communicating with said bore;(b) an ultrasonic receiver or transmitter device (318) connected to said housing for receiving or transmitting an intermittent signal, said ultrasonic receiver or transmitter device (318) having an annular configuration and surrounding said central orifice (308),wherein the handheld device further comprises a removably attachable operative implement (312) for insertion through said orifice to be received within said bore with its operative tip (314) extending from said central orifice, said operative implement being selected from the group consisting of a drawing implement and an annotation implement,and wherein said housing includes a retainer (316) in said housing for releasably retaining said removably attachable operative implement (312) within said housing.


PubMed | Pegasus Technologies
Type: Evaluation Studies | Journal: Fertility and sterility | Year: 2011

To present a report on assisted reproductive technologies (ART) cycles performed in 2007 in Canada and show trends in outcomes over time. This is the seventh annual report from the Canadian ART Register (CARTR).Prospective cohort study.Twenty-six of 26 ART centers in Canada.Couples undergoing ART treatment in Canada during 2007.ART treatments, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and frozen embryo transfer (FET).Clinical pregnancy, live-birth, and multiple-birth rates.A total of 13,482 ART cycles was reported to CARTR. In 8,972 IVF/ICSI cycles using the womans own oocytes, per cycle started, the clinical pregnancy rate was 35.6% (41.0% per ET), and the live-birth rate was 28.6%; the multiple-birth rate per delivery was 30.2%, with a high-order multiple-birth rate of 1.1%. In 68% of cycles ICSI was performed. One or two embryos were transferred in 69% of cycles. In 404 IVF/ICSI cycles using donor oocytes, the clinical pregnancy rate was 44.6%, and the live-birth rate was 36.1%; the multiple-birth rate was 26.5%, with no triplet birth. In 3,224 FET cycles using the womans own oocytes, the clinical pregnancy rate was 23.7%, and the live-birth rate was 17.8%; the multiple-birth rate was 24.1%, with a triplet birth rate of 0.2%. Birth outcomes were unknown for 2.0% of ongoing pregnancies.For 2007, CARTR achieved 100% voluntary participation from Canadian ART centers for the fifth consecutive year. Clinical pregnancy and live-birth rates continued to increase in 2007 compared with previous years, with a decrease in high-order multiple births.


PubMed | Pegasus Technologies
Type: Evaluation Studies | Journal: Fertility and sterility | Year: 2010

To present a report on assisted reproductive technologies (ART) cycles performed in 2006 in Canada and show trends in outcomes over time. This is the sixth annual report from the Canadian ART Register (CARTR).Prospective cohort study.Twenty-five of 25 ART centers in Canada.Couples undergoing ART treatment in Canada during 2006.ART treatments, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and frozen embryo transfer (FET).Clinical pregnancy, live birth, and multiple birth rates.A total of 12,052 ART cycles was reported to CARTR. In 8278 IVF/ICSI cycles using the womans own oocytes, the clinical pregnancy rate per cycle started was 33.7% (38.6% per ET), and the live birth rate was 27.1%; the multiple birth rate per delivery was 30.3%, with a high-order multiple birth rate of 1.5%. In 64% of cycles, ICSI was performed. One or two embryos were transferred in 67% of cycles. In 350 IVF/ICSI cycles using donor oocytes, the clinical pregnancy rate was 42.3%, and the live birth rate was 33.6%; the multiple birth rate was 37.3%, with no triplet birth. In 2838 FET cycles using the womans own oocytes, the clinical pregnancy rate was 24.3%, and the live birth rate was 18.6%; the multiple birth rate was 22.5%, with a triplet birth rate of 0.6%. Birth outcomes were unknown for 3.6% of ongoing pregnancies.For 2006, CARTR achieved 100% voluntary participation from Canadian ART centers for the fourth consecutive year. Clinical pregnancy and live birth rates continued to increase in 2006 compared with previous years, but multiple birth rates decreased only slightly.


PubMed | Pegasus Technologies
Type: Journal Article | Journal: Biomedical microdevices | Year: 2016

We describe a new wound dressing technology that can actively generate an inorganic germicide agent, in situ, within the wound pad. The technology provides real time control over the quantitative, spatial and temporal delivery of the germicide. The identity of the germicide is hypochlorous acid (HClO). The HClO is produced in a flexible wound pad, made of a composite of thin (micrometer scale) layers of various materials, with different electrochemical propertiesthat enhance HClO production. Active control over the production of HClO is achieved by control of the pH and of the electric potential across the layers. The effectiveness of the Active HClO Pad (AHClOP) concept is demonstrated in a study on sterilization of E. coli in a deep wound contamination simulating gel. The performance of the AHClOP is compared with that of four commercial wound dressings. Results show that the AHClOP can sterilize throughout the gel, while the commercial dressings cannot.


News Article | July 28, 2000
Site: www.zdnet.com

26 July 2000 - The Neugent ii offering, already being used by CitiStreet, Pegasus Technologies and New Scotland Yard, will bring to applications the ability to predict business outcomes or opportunities by observing patterns of activity. The artificial intelligence-like technology is used in existing CA applications such as Unicenter TNG to watch network traffic patterns and predict potential performance problems. It is also a part of CA's Jasmine ii offering.


Loading Pegasus Technologies collaborators
Loading Pegasus Technologies collaborators